References
Badmaev V, Majeed M, Conte AA. Garcinia cambogia for weight loss [letter; comment]. Jama 1999;282:233-4; discussion 235.
Firenzuoli F, Gori L. Garcinia cambogia for weight loss [letter]. Jama 1999;282:234; discussion 235.
Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial [see comments]. Jama 1998;280:1596-600.
Hoeger WW, Harris C, Long EM, Hopkins DR. Four-week supplementation with a natural dietary compound produces favorable changes in body composition. Adv Ther 1998;15:305-14.
Kriketos AD, Thompson HR, Greene H, Hill JO. (-)-Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state. Int J Obes Relat Metab Disord 1999;23:867-73.
McCarty MF. Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics. Med Hypotheses 1998;51:399-403.
Schaller JL. Garcinia cambogia for weight loss [letter; comment]. Jama 1999;282:234; discussion 235
http://naturaldatabase.therapeuticresearch.com/nd/Search.aspx?cs=GUARANA&s=ND&pt=9&Product=guarana
Adnot S et al. Forskolin: a powerful inhibitor of human platelet aggregation. Biochemical Pharmacology 1982;31:4071- 4074.
Baumann G et al. Cardiovascular effects of forkolin (HL 362) in patients with idiopathic congestive cardiomyopathy – a comparative study with dobutamine and sodium nitroprusside. J Cardiovasc Pharmacol 1990;16(1):93-100.
Bhat SV et al. The antihypertensive and positive inotropic diterpene forskolin: effects of structural modifications on its activity. Journal of Med Chem 1983;26:486-492.
de Souza NJ, Dohadwalla AN, Reden J. Forskolin: a labdane diterpenoid with antihypertensive, positive inotrpic, platelet aggregation inhibitory, and adenylate cyclase activating properties. Med Res Rev 1983;3(2):201-19.
Kreutner RW et al. Bronchodilator and antiallergy activity of forskolin. European Journal of Pharmacology 1985;111:1-8.
Laurberg P. Forskolin stimulation of thyroid secretion of T4 and T3. FEBS Letters 1984;170:273-275.
Laurenza A, Sutkowski EM, Seamon KB. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? Trends Pharmacol Sci 1989;10(11):442-7.
Linder E, Dohadwalla AN, bhattacharya BK. Positive inotropic and blood pressure lowering activity of a diterpene derivative isolated from Coleus forskohlii: forskolin. Arzneimittel forschung 1978;28:284-289.
Marone G et al. Inhibiton of IgE-mediated release of histamine and peptide leukotriene from human basophil and mast cells by forskolin. Biochem Pharmacol 1987;36(1):13-20.
Okuda H, Morimoto C, Tsujita T. Relationship between cyclic AMP production and lipolysis induced by forskolin in rat fat cells. Journal of Lipid Research 1992;33:225-231.
Mulhall JP et al. Intracavernosal forskolin: role in management of vasculogneic impotence resistant to standard 3-agent pharmacotherapy. J Urol 1997;158(5):1752-8.
Seamon KB, Daly JW. Forskolin: a unique diterpene activator of cyclic AMP-generating systems. Journal of Cyclic Nucleotide Research; 1981;7:201-225.
Seamon KB, Daly JW. Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res 1986;20:1-150.
Snow JM. Herbal monograph: Coleus forskohlii WILLD. (Lamiaceae). The Protocol Journal of Botanical Medicine 1995:39-42.
Deutsch SI, Rosse RB, Schwartz BL, Banay-Schwartz M, McCarthy MF, Johri SK. L-tyrosine pharmacotherapy of schizophrenia: preliminary data. Clin Neuropharmacol 1994;17:53-62.
Elwes RD, Crewes H, Chesterman LP, et al. Treatment of narcolepsy with L-tyrosine: double-blind placebo-controlled trial. Lancet 1989;2:1067-1069.
Lou HC, Lykkelund C, Gerdes AM, Udesen H, Bruhn P. Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr Scand 1987;76:560-565.
Moller SE, Maach-Moller B, Olesen M, Madsen B, Madsen P, Fjalland B. Tyrosine metabolism in users of oral contraceptives. Life Sci 1995;56:687-695.
Neri DF, Wiegmann D, Stanny RR, Shappell SA, McCardie A, McKay DL. The effects of tyrosine on cognitive performance during extended wakefulness. Aviat Space Environ Med 1995;66:313-319.
Salter CA. Dietary tyrosine as an aid to stress resistance among troops. Mil Med 1989;154:144-146.
Shurtleff D, Thomas JR, Schrot J, Kowalski K, Harford R. Tyrosine reverses a cold-induced working memory deficit in humans. Pharmacol
Biochem Behav 1994;47:935-941.
Sole MJ, Benedict CR, Myers MG, Leenen FH, Anderson GH. Chronic dietary tyrosine supplements do not affect mild essential hypertension.
Hypertension 1985;7:593-596.
Zeisel SH. Dietary influences on neurotransmission. Adv Pediatr 1995;33:23-47.
Bu-Abbas A et al. Marked antimutagenic potential of aqueous green tea extracts: mechanism of action. Mutagenesis 1994;9:325-331.
Gao YT et al. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst 1994;86:855-858.
Geleijnse JM, Launer LJ, Hofman A, Pols HA, Witteman JC. Tea flavonoids may protect against atherosclerosis: the Rotterdam Study. Arch Intern Med 1999;159:2170-2174.
Klaunig JE. Chemopreventive effects of green tea components on hepatic carcinogenesis. Prev Med 1992;21:510-519.
Mukhtar H et al. Green tea and skin--anticarcinogenic effects. J Invest Dermatol 1994;102:3-7.
Nakayama M et al. Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res 1993;21:289-299.